Pushing Hard On PD-1, Merck Signs Trio Of Combo Development Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s oncology build-up is continuing, even as it tightens focus and squeezes spending in other parts of its business as part of an ongoing “reshaping” that CFO Peter Kellogg said will help to maximize “core in-line assets and key pipeline programs” that are critical for growth.